Becton, Dickinson and Company Q4 2026 Earnings Recap

BD reported Q4 revenue of $5.3 billion, up 5.6%, and adjusted EPS of $4.15, up 27.3%; the stock rose 2.1%, a roughly flat reaction. The results were mixed across a portfolio with growth platforms gaining momentum, while full-year revenue growth was 3.9%.

Key Takeaways

• Full-year revenue was $19.5 billion, up 3.9%, and adjusted EPS was $12.70, up 6.7%.
• Management said revenue growth excluding the Alaris prior-year comparison was high single-digit in Q4 and solid mid-single-digit for the full year.
• Advanced Patient Monitoring, PureWick, advanced tissue regeneration, biologic drug delivery, and Rowa pharmacy automation each delivered double-digit growth in Q4 and for the full year, with accretive margins.
• Alaris gained more than 250 basis points of share for the full year; BD also reported strong Pyxis Pro order momentum and a 95% attachment rate for its Incada AI platform.
• BD committed to $19 billion of U.S. investment over several years, including $3 billion for manufacturing expansion; the company said this reprioritizes planned investment rather than adding to it.